Clinical Research Directory

CXCL9 and EASIX for Prediction of Acute Graft Versus Host Disease

Sponsor: Henry Ford Health System

Summary

The prediction of severe acute GVHD before it occurs is of high importance for ensuing clinical decisions and overall success of allogeneic SCT. The key immunologic signatures associated with clinical outcomes after different graft versus host disease prophylaxis methods or peripheral blood stem cell transplant are largely unknown.

Official title: CXC-chemokine Ligand 9 (CXCL9) and Endothelial Activation and Stress Index (EASIX) for Prediction of Acute Graft Versus Host Disease

Key Details

Conditions

Interventions

Locations (1)